Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Insmed (INSM) to $180 from $110 and keeps an Outperform rating on the shares. The firm sees Insmed entering its “next big growth phase” with Brinsupri launching in NCFB, the analyst tells investors. Phase 3 CRSsNP data due by year-end 2025 could yield “yet another” roughly $3B opportunity, the analyst contends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Measured Optimism and Caution: Maxwell Skor’s Hold Rating on Insmed Amid Promising Brinsupri Launch
- Insmed to present multiple abstracts from ERS Congress 2025
- Promising Market Potential for Insmed’s Brensocatib Drives Buy Rating
- Insmed price target raised to $172 from $125 at Guggenheim
- Insmed’s Strategic Advancements and Market Potential: A Buy Recommendation